UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Three-monthly dynamic evaluation of CEA and CA15-3 and 18-FDG PET vs usual practice in the follow-up of early breast cancer patients: a prospective, multicenter, randomized trial (KRONOS – Patient-Oriented New Surveillance-Study Italy)

Annals of oncology, 2017-10, Vol.28, p.vi81-vi81

2017

Volltextzugriff (PDF)

Abstract OT3-05-01: Three-monthly dynamic evaluation of CEA and CA15-3 (followed by 18-FDG PET) vs usual practice in the follow-up of early breast cancer (BC) patients (pts): A prospective randomized trial (KRONOS-patient-oriented new surveillance study, Italy)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT3-05-01-OT3-05-01

2017

Volltextzugriff (PDF)

Neoadjuvant chemotherapy in breast cancer – prediction of pathological response by FDG PET

European journal of cancer supplements, 2008, Vol.6 (7), p.62-62

2008

Volltextzugriff (PDF)

Sociologie de l'énergie : Gouvernance et pratiques sociales

2015

Volltextzugriff (PDF)

CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study

European journal of cancer (1990), 1995-09, Vol.31 (10), p.1615-1621

1995

Volltextzugriff (PDF)

The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support?

European journal of gynaecological oncology, 2000, Vol.21 (1), p.84

2000

Volltextzugriff (PDF)

Predictive role of [18F]FDG-PET early evaluation in patients (pts) undergoing preoperative chemotherapy (PCT) for breast cancer (BC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.635-635

2010

Volltextzugriff (PDF)

Effect of six courses of neoadjuvant chemotherapy on pathological complete remission in advanced ovarian cancer

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.5513-5513

2009

Volltextzugriff (PDF)

Advanced ovarian cancer patients with no evidence of disease after platinum-based chemotherapy: retrospective analysis of the role of second-look

European journal of gynaecological oncology, 1999, Vol.20 (1), p.56

1999

Volltextzugriff (PDF)

Long-term toxicity of high-dose sequential chemotherapy with autologous hematopoietic stem cells support in very high-risk early breast cancer patients (pts)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.11101-11101

2007

Volltextzugriff (PDF)

Response to primary chemotherapy (CHT) in advanced epithelial ovarian cancer (EOC) patients (pts) and molecular characterization of CHT-resistant tumor cell populations: Findings from the Arianna 02 Project

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.16059-16059

2007

Volltextzugriff (PDF)

Early evaluation of response to neoadjuvant chemotherapy in stage IIIC-IV epithelial ovarian cancer patients by 18 FDG-PET and CA 125: Preliminary findings from the Arianna Project 02

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.15039-15039

2006

Volltextzugriff (PDF)

Mobilités et socialisations

Espaces et sociétés (Paris, France), 2022 (184-185)

2022

Volltextzugriff (PDF)

Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies

Cancer chemotherapy and pharmacology, 1995, Vol.36 (4), p.356-359

1995

Volltextzugriff (PDF)

Correlation between FDG-PET and pathologic response in patients with rectal cancer treated with neoadjuvant chemo-radiotherapy: First results of the Bologna Project

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3623-3623

2005

Volltextzugriff (PDF)

CA-549 serum levels in breast cancer monitoring

The International journal of biological markers, 1992-10, Vol.7 (4), p.217-221

1992

Volltextzugriff (PDF)

Chemotherapy of advanced ovarian cancer

Frontiers in bioscience, 1997-03, Vol.2, p.g20

1997

Volltextzugriff (PDF)

The combination of paclitaxel and carboplatin as first-line chemotherapy in patients with stage III and stage IV ovarian cancer a phase I-II study

American journal of clinical oncology, 1998-10, Vol.21 (5), p.491-497

1998

Volltextzugriff (PDF)

510 A phase I study of paclitaxel (taxol ®) (TXL) and carboplatin (CBDCA) in the treatment of advanced ovarian cancer

European journal of cancer (1990), 1995-11, Vol.31, p.S109-S109

1995

Volltextzugriff (PDF)

523 Tolerability of paglitaxel (Taxol ®) in platinum pretreated advanced ovarian cancer patients

European journal of cancer (1990), 1995-11, Vol.31, p.S111-S112

1995

Volltextzugriff (PDF)

Single and multiple dose pharmacokinetics of letrozole (® Femara) in elderly and younger postmenopausal patients (pts) with advanced breast cancer

European journal of cancer (1990), 1999-09, Vol.35, p.S292-S293

1999

Volltextzugriff (PDF)

PP-1-17 Circulating tumor markers (CEA, MCA, CA 15.3, CA 549) in the diagnosis breast cancer recurrence after surgery: 5-Year results

European journal of cancer (1990), 1996, Vol.32, p.13-13

1996

Volltextzugriff (PDF)

1254 Predictivity of circulating tumor markers (CEA, MCA, CA 15.3, CA 549) in breast cancer recurrence after surgery

European journal of cancer (1990), 1995-11, Vol.31, p.S262-S262

1995

Volltextzugriff (PDF)

Medroxyprogesterone- and megestrol acetate plasma levels after simultaneous oral administration in cancer patients

European journal of cancer (1990), 1993, Vol.29, p.S112-S112

1993

Volltextzugriff (PDF)

A new regimen of cisplatin, epirubicin and methotrexate (PEM-3) as primary chemotherapy for locally advanced bladder cancer

Tumori, 1996-07, Vol.82 (4), p.364

1996

Volltextzugriff (PDF)

1 – 25 von 166

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(127)
Mit Volltextzugriff
(134)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Three-monthly dynamic evaluation of CEA and CA15-3 and 18-FDG PET vs usual practice in the follow-up of early breast cancer patients: a prospective, multicenter, randomized trial (KRONOS – Patient-Oriented New Surveillance-Study Italy)

Abstract OT3-05-01: Three-monthly dynamic evaluation of CEA and CA15-3 (followed by 18-FDG PET) vs usual practice in the follow-up of early breast cancer (BC) patients (pts): A prospective randomized trial (KRONOS-patient-oriented new surveillance study, Italy)

Neoadjuvant chemotherapy in breast cancer – prediction of pathological response by FDG PET

Sociologie de l'énergie : Gouvernance et pratiques sociales

CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study

The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support?

Predictive role of [18F]FDG-PET early evaluation in patients (pts) undergoing preoperative chemotherapy (PCT) for breast cancer (BC)

Effect of six courses of neoadjuvant chemotherapy on pathological complete remission in advanced ovarian cancer

Advanced ovarian cancer patients with no evidence of disease after platinum-based chemotherapy: retrospective analysis of the role of second-look

Long-term toxicity of high-dose sequential chemotherapy with autologous hematopoietic stem cells support in very high-risk early breast cancer patients (pts)

Response to primary chemotherapy (CHT) in advanced epithelial ovarian cancer (EOC) patients (pts) and molecular characterization of CHT-resistant tumor cell populations: Findings from the Arianna 02 Project

Early evaluation of response to neoadjuvant chemotherapy in stage IIIC-IV epithelial ovarian cancer patients by 18 FDG-PET and CA 125: Preliminary findings from the Arianna Project 02

Mobilités et socialisations

Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies

Correlation between FDG-PET and pathologic response in patients with rectal cancer treated with neoadjuvant chemo-radiotherapy: First results of the Bologna Project

CA-549 serum levels in breast cancer monitoring

Chemotherapy of advanced ovarian cancer

The combination of paclitaxel and carboplatin as first-line chemotherapy in patients with stage III and stage IV ovarian cancer a phase I-II study

510 A phase I study of paclitaxel (taxol ®) (TXL) and carboplatin (CBDCA) in the treatment of advanced ovarian cancer

523 Tolerability of paglitaxel (Taxol ®) in platinum pretreated advanced ovarian cancer patients

Single and multiple dose pharmacokinetics of letrozole (® Femara) in elderly and younger postmenopausal patients (pts) with advanced breast cancer

PP-1-17 Circulating tumor markers (CEA, MCA, CA 15.3, CA 549) in the diagnosis breast cancer recurrence after surgery: 5-Year results

1254 Predictivity of circulating tumor markers (CEA, MCA, CA 15.3, CA 549) in breast cancer recurrence after surgery

Medroxyprogesterone- and megestrol acetate plasma levels after simultaneous oral administration in cancer patients

A new regimen of cisplatin, epirubicin and methotrexate (PEM-3) as primary chemotherapy for locally advanced bladder cancer

Suchergebnisse filtern